drugset / Trial / NCT06343298
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Phase 2
Recruiting
120 enrolled
E-Star BioTech, LLC
Mayo Clinic · collabPPD Development, LP · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Timeline
- Start
- 2024-11-17
- Primary completion
- 2026-07-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MANP | Peptide | — | Subcutaneous |